Qynapse
Qynapse is a Paris-based medical technology company that develops FDA-cleared and CE-marked AI-powered neuroimaging software (QyScore) and predictive analytics (QyPredict) for diagnosis, monitoring, and clinical trial enrichment in central nervous system diseases, serving healthcare providers, pharmaceutical sponsors, payers, and academic researchers globally.
- Company typePrivate
- Founded2015
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Qynapse does
Qynapse is a privately-held medical technology company founded in 2015 in Paris as a spin-off from the CATI consortium of neuroimaging research laboratories. It develops AI-powered neuroimaging software for the screening and monitoring of central nervous system (CNS) diseases such as Alzheimer's disease, multiple sclerosis and Parkinson's disease, with operating offices in Paris (headquarters), Boston (North America) and Montreal (engineering/R&D, established through the 2020 acquisition of TRUE POSITIVE MEDICAL DEVICES Inc.). Its commercial platform is built around two core products: QyScore, an FDA-cleared (Class II, February 2020) and CE-marked (Class IIa, September 2017) medical device software that performs automated labeling, visualization and volumetric quantification of brain structures and lesions from MRI scans; and QyPredict, a research-use-only machine learning platform that combines MRI with PET, genomics, biofluids and cognitive endpoints to predict disease trajectory and support patient selection and enrichment in clinical trials. The platform is underpinned by a proprietary normative dataset of over 10,000 brain scan images and a portfolio of 15 patents (9 issued in the US and Canada).
Qynapse serves four primary customer segments: healthcare providers (neurologists, radiologists, hospitals and clinics using QyScore for diagnosis and monitoring), pharmaceutical and biotech companies (using QyScore and QyPredict as imaging endpoints and patient enrichment tools in CNS clinical trials), payers (positioned as decision-support partners in the CNS care pathway) and academic research institutions (collaborators for clinical validation). Its go-to-market is a B2B enterprise sales motion combining direct field sales with channel partnerships, notably Calyx (clinical trial services distribution since 2022) and AG Mednet (imaging data transfer infrastructure since 2018), and sustained presence at major industry conferences including AAIC, AD/PD, RSNA, ECR, CTAD, ACTRIMS, EAN and SFNR. Pricing is not publicly disclosed and is structured as enterprise subscription licensing for healthcare providers and multi-year custom contracts for clinical trial services.
Revenue mechanics derive from two streams: software licensing for QyScore (subscription/recurring revenue model) and clinical trial services delivered to pharmaceutical sponsors (project-based or multi-year contracts). Disclosed funding is approximately $6.6 million across three rounds in 2018, 2020 and 2021, and the company reported preparation for a larger Series A raise to accelerate global growth. Revenue figures, customer counts and detailed commercial metrics are not publicly disclosed.
Qynapse firmographics
Firmographics- Name
- Qynapse
- Legal name
- QYNAPSE SAS
- Website
- https://qynapse.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Qynapse is a Paris-based medical technology company that develops FDA-cleared and CE-marked AI-powered neuroimaging software (QyScore) and predictive analytics (QyPredict) for diagnosis, monitoring, and clinical trial enrichment in central nervous system diseases, serving healthcare providers, pharmaceutical sponsors, payers, and academic researchers globally.
- Ownership category
- akta.pro rank
Qynapse industry classification
Industry- Product category
- Neuroimaging Software
- NAICS
- Computer Systems Design and Related Services (54151), Scientific Research and Development Services (5417)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)
- akta.pro secondary industry
- Medical Imaging AI (HDAAAEAH)
Keywords
Where Qynapse is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices3 records
Markets served
Qynapse business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- QyScore® Software Licensing: FDA-cleared and CE-marked medical device software commercialized for clinical routine and clinical trial applications. Sold to healthcare providers (hospitals, clinics) and pharmaceutical companies. Revenue from software licensing, likely subscription or usage-based model.
- Clinical Trial Services: Providing AI-powered neuroimaging analysis services to pharmaceutical companies conducting CNS clinical trials. Supports patient selection, endpoint measurement, and drug efficacy assessment. Partnership with Calyx for broader clinical trial imaging services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise licensing for healthcare providers |
| Other | Multi-year contract | Clinical trial services for pharmaceutical companies |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Qynapse product offering
Product offeringCore offering
Qynapse develops and commercializes an AI-powered neuroimaging software platform that combines MRI scans with proprietary algorithms for automated brain image segmentation, volumetric quantification, and disease prediction. Its flagship product QyScore® is an FDA-Cleared (Class II) and CE-Marked (Class IIa) medical device software, while QyPredict® is a research-use-only predictive platform leveraging machine learning on multi-modal data to predict disease progression and enable patient selection enrichment for CNS clinical trials.
Product overview
Qynapse offers an integrated AI-powered neuroimaging platform combining two core products: QyScore® and QyPredict®. QyScore® is the FDA-Cleared and CE-Marked flagship software that provides automated quantitative MRI analysis including brain segmentation, volumetric measurements, and white matter lesion quantification. QyPredict® is the research-use-only predictive analytics module that leverages QyScore® outputs combined with multi-modal data (MRI, PET, genomics, biofluids, cognitive endpoints) using machine learning algorithms to predict disease progression and enrich patient selection in clinical trials. The platform is built on a proprietary normative dataset of over 10,000 brain scan images and 20 algorithms.
Differentiator
Problem solved
Functional benefit
Brands
- QyScore®: FDA-Cleared and CE-marked neuroimaging analysis platform for automated quantification of brain MRI markers for clinical routine and clinical trials. Produces measures of neuroinflammation and neurodegeneration including whole brain, white matter, grey matter, and brain substructures.
- QyPredict®
Products and services
- QyScore® FDA-Cleared (Class II) and CE-Marked (Class IIa) AI-powered neuroimaging software providing automated labeling, visualization and volumetric quantification of segmentable brain structures and lesions from MR images, producing measures of neuroinflammation and neurodegeneration to support clinical diagnosis and monitoring of CNS diseases for healthcare providers and pharmaceutical companies.
- QyPredict® Research-use-only AI-powered predictive platform that combines MRI data, genomics, biofluids, and cognitive endpoints with machine learning to predict individual disease trajectory and enable patient selection enrichment for CNS clinical trials. Protected by 3 patents.
Quantifiable outcome
- 89% reduction in image reading variability and segmentation errors
- +4 more outcomes
Companies that use Qynapse
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles2 records
Qynapse technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature4 records
Qynapse partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered significant, core and minor.
- Amsterdam UMCsignificantLandmark study published in Alzheimer's Research & Therapy analyzing post-mortem and ante-mortem MRI data using QyScore. Linked structural brain atrophy with key AD pathologies including amyloid-beta, pTau, neurofilament light, and vascular markers across typical and atypical AD phenotypes.
- University of Miami Miller School of MedicinesignificantCollaborative project funded by NIH to examine COVID-19 effects on vascular contributions to cognitive impairment and dementia (VCID). QyScore deployed for MRI analysis of 250 patients. Also partnerships for dementia screening study (500 individuals) and Parkinson's disease research funded by Michael J. Fox Foundation.
- CalyxcorePartnership enables Calyx to adopt and deliver Qynapse's QyScore and QyPredict to its global pharmaceutical and biotech customers as part of comprehensive CNS clinical trial services. Calyx has proven services in over 2,600 global clinical trials supporting 270+ treatment approvals.
- Brigham and Women's HospitalsignificantImportant collaboration with Center for Neurological Imaging at Brigham and Women's Hospital to advance MS research and clinical care. Dr. Charles R.G. Guttmann leading collaboration to validate neuroimaging solutions for multiple sclerosis.
- Decentralized Trials & Research Alliance (DTRA)minorQynapse joined DTRA coalition of 50+ life sciences organizations working to accelerate adoption of patient-focused, decentralized clinical trials. Contributes expertise to advance best practices through education and communication.
- TRUE POSITIVE MEDICAL DEVICES Inc. (TPMD)coreStrategic acquisition of Canadian company TPMD, a spin-off from McGill and Laval universities. Objective to combine TPMD's technologies, patents (15 patents including 9 US/Canada) and expertise with Qynapse's product line to form most advanced AI platform in brain imaging. TPMD founders Prof. Louis Collins (McGill) and Prof. Simon Duchesne (Laval) joined Qynapse's scientific board.
- University of VeronaminorCollaboration to investigate long-term brain damages in COVID-19 patients presenting symptoms of anosmia and ageusia. Study using QyScore to analyze brain MRI markers and understand CNS impact of SARS-CoV-2.
- AG MednetcorePartnership for AG Mednet's Judi imaging adjudication system to secure medical image collection and transfer from multiple sites and countries. Ensures data quality, compliance, anonymization, and security for clinical trial analyses.
Scale indicators5 records
Recent moves8 records
Expansion highlights6 records
Qynapse competitors and assessment
Company assessmentEmerging players
- Subtle Medical: Subtle Medical applies deep learning to enhance MRI and PET image acquisition speed and quality — addressing adjacent pain points in CNS imaging workflows and serving similar pharma and clinical research customers.
- Blackford Analysis: Blackford Analysis provides an AI application marketplace and platform for medical imaging interpretation, including some CNS-related tools — adjacent to Qynapse through shared radiology channel partners and enterprise imaging integrations.
Broad incumbents
- Aidoc: Aidoc is a well-capitalized AI medical imaging vendor offering FDA-cleared triage and workflow solutions across multiple anatomies — overlapping with Qynapse's enterprise hospital sale motion, but with a much broader portfolio and not specialized in CNS quantification.
- Arterys (Tempus): Arterys, now part of Tempus, offers a cloud-based AI medical imaging platform with FDA-cleared applications across multiple modalities and anatomies — providing overlapping infrastructure and pharma services capability, but as a broader portfolio player rather than a brain-focused specialist.
Direct peers
- Perspectum: Perspectum develops quantitative MRI analysis platforms (e.g., LiverMultiScan and brain imaging tools) and sells to pharma sponsors and clinical research — overlapping with Qynapse in pharma trial imaging services and multi-modal biomarker positioning.
- Quibim: Quibim provides AI-powered quantitative imaging biomarkers across multiple organ systems including the brain, with a similar focus on pharma clinical trial imaging endpoints and radiology decision support — directly comparable in go-to-market and product scope.
- Brainreader ApS: Brainreader offers Neuroreader, an AI-driven brain MRI volumetric analysis tool aimed at radiology practices — overlapping with Qynapse on automated brain structure quantification and clinical routine use cases.
- Cortechs.ai: Cortechs.ai markets NeuroQuant, an FDA-cleared AI tool for volumetric brain MRI analysis, directly competing with QyScore® in clinical radiology and clinical trial imaging endpoint applications.
- icometrix: icometrix develops AI-based brain MRI quantification software (icobrain) for multiple sclerosis, Alzheimer's, and other neurological conditions — directly overlapping with Qynapse's QyScore® product in indications, regulatory pathway, and clinical trial customer base.
Others
- Viz.ai: Viz.ai is a high-profile AI imaging company focused on stroke and acute care workflow — not a direct CNS quantification competitor, but a relevant comparator for AI imaging regulatory strategy, enterprise hospital GTM, and pharma-adjacent commercialization.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Qynapse social profiles
Digital presenceQynapse compliance and trust
Trust signalCompliance4 records
Qynapse financial estimates
Financial estimateRevenue estimate
Valuation estimate
Qynapse leadership team
Management profileNumber of profiles
Profiles6 records
Qynapse subsidiaries and ownership
Company hierarchySubsidiaries1 record
Qynapse funding detail
Funding detailFunding overview
Funding rounds4 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Qynapse M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Qynapse
What does Qynapse do?
Qynapse develops and commercializes an AI-powered neuroimaging software platform that combines MRI scans with proprietary algorithms for automated brain image segmentation, volumetric quantification, and disease prediction. Its flagship product QyScore® is an FDA-Cleared (Class II) and CE-Marked (Class IIa) medical device software, while QyPredict® is a research-use-only predictive platform leveraging machine learning on multi-modal data to predict disease progression and enable patient selection enrichment for CNS clinical trials.
Is Qynapse a public or private company?
Qynapse is a private company. It is classified as venture growth investor backed and is currently operating.
When was Qynapse founded?
Qynapse was founded in 2015. It employs 11 to 50 people.
Where is Qynapse based?
Qynapse is headquartered in Paris, France, in the Europe region.
How does Qynapse make money?
Two revenue lines are on record. QyScore® Software Licensing is the primary driver. The others are clinical Trial Services.
Who are Qynapse's main competitors?
Emerging players on record are Subtle Medical and Blackford Analysis. Broad incumbents are Aidoc and Arterys (Tempus). Direct peers are Perspectum, Quibim, Brainreader ApS, Cortechs.ai and icometrix. Viz.ai is listed as an others.
Does Qynapse have an API?
No public API is recorded for Qynapse.
What industry is Qynapse in?
Qynapse's product category is Neuroimaging Software. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 54151 and its SIC code is 7372.